u/ysh1324 · 317d agono track record yet
SLS ($1.75) - Phase 3 AML Trial Readout by Year-End: Hype Building for a Potential 4x-5x Runner? Full DD on Sellas Life Sciences
Sellas Life Sciences is developing GPS vaccine and SLS009 inhibitor for AML. Phase 3 REGAL readout expected by year-end with survival data (23 vs. 11 months in Phase 2); positive results could trigger FDA filing and 2-5x upside. Near-term ASH conference data presentation (early Phase 2 results) offers additional catalyst.
At post $1.82Now $10.72+489.0% since postedas of Oct 19, 11:31 AM ET
1d—
3d+4.4%
1w+11.5%
1m+174.7%
3m+203.8%
6m+396.7%
1y—